Table 1.
Baseline Participant Characteristics
| Variable | Efficacy/safety population (n = 90) |
|---|---|
| Age, years (SD) | 45.1 (16.2) |
| Gender, n (%) | |
| Male | 54 (60.0) |
| Female | 36 (40.0) |
| Race, n (%) | |
| Caucasian | 77 (85.6) |
| Black or African American | 7 (7.8) |
| Asian | 3 (3.3) |
| American Indian or Alaska Native | 2 (2.2) |
| Native Hawaiian or Other Pacific Islander | 1 (1.1) |
| BMI, kg/m2 (SD) | 29.1 (6.2) |
| Years since diabetes diagnosis, years (SD) | 20.1 (13.7) |
| Diabetes type, n (%) | |
| T1D | 61 (67.8) |
| T2D | 29 (32.2) |
| HbA1c, % (SD) | 7.6 (1.2) |
| Diabetes therapy, n (%) | |
| Oral or diet and exercisea | 22 (24.4) |
| Long acting insulinb | 1 (1.1) |
| Multiple daily injectionsc | 24 (26.7) |
| Insulin pumpd | 43 (47.8) |
| History of ketoacidosis, n (%) | 0 (0) |
| History of severe hypoglycemia, n (%) | 1 (1.1) |
a
Participants with T2D.
b
Participant with T2D.
c
Includes four participants with T2D.
d
Includes two participants with T2D.
BMI, body mass index; HbA1c, hemoglobin A1c; SD, standard deviation; T1D, type 1 diabetes; T2D, type 2 diabetes.